Stock ORY ORYZON GENOMICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

All News Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Real-time Estimate Tradegate
Other stock markets
 15:16:20 08/05/2024 BST 		5-day change 1st Jan Change
1.965 EUR +0.67% Intraday chart for Oryzon Genomics S.A. +3.14% +4.34%
05-06 Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-22 Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Oryzon Genomics S A : reports financial results and corporate update for quarter ended March 31, 2024
PU
Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
CI
Oryzon Genomics S A : secures another important patent for its lead CNS asset, vafidemstat
PU
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
AQ
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
CI
Oryzon Genomics S A : to provide corporate progress updates at several events in April
PU
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023
AQ
Oryzon Genomics S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
ORYZON to Provide Corporate Progress Updates at Several Events in February-March
AQ
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
AQ
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)
AQ
Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder
CI
ORYZON to Provide Corporate Progress Updates at Several Events in January
AQ
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.
AQ
ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million
AQ
Oryzon Genomics S.A. announced that it expects to receive ?45 million in funding from Nice & Green SA
CI
Oryzon Completes Patient Testing in Mid-stage Study of Borderline Personality Disorder Drug
MT
ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)
AQ
Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ORY Stock
  4. News Oryzon Genomics S.A.